theracim - Nimotuzumab for Locally Advanced Head and kode keamanan cvv Neck Squamous Cell Carcinoma LAHNSCC A total of more than 46 clinical trials have been completed with Nimotuzumab for various cancer indications worldwide with more than 4382 patients enrolled in the trials Nimotuzumab has been studied in ten clinical trials at HNSCC conducted in Canada Cuba and IndiaIn addition there are ongoing studies in About TheraCIM Nimotuzumab TheraCIM hR3 Home Nimotuzumab TheraCIM hR3 Theracim KlikDokter TheraCIM binds to EGFR with intermediate affinity 10 8 and 10 9 M causing high tumour uptake and low uptake in normal tissue This results in effective EGFR blockade without causing deleterious effects on the skin because the optimal dose is far lower than the toxic dose Anti Cancer properties of TheraCIM Antiproliferative activity Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer Nimotuzumab SpringerLink Nimotuzumab alternatively referred to as TheraCIM Theraloc CIMAher BIOMAbEGFR Tai Xin Sheng OSAG101 or YMB1000 is a humanized IgG1 monoclonal antibody targeting the extracellular domain of EGFR It has demonstrated blocking ability against the binding of EGF and TGFalpha to EGFR Nimotuzumab Wikipedia Background The efficacy of a combination of nimotuzumab a humanized monoclonal antibody to the epidermal growth factor receptor with chemoradiation in locally advanced head and neck squamous cell carcinoma HNSCC was evaluated in a phase II study Methods Patients with stage IIIIV HNSCC received 3weekly cisplatin 100 mgm 2 for three cycles and weekly nimotuzumab 200 mg for 8 weeks Nimotuzumab TheraCIM Theraloc CIMAher BIOMAb EGFR YM CIMYM Biosciences is an IgG1k humanized monoclonal antibody binding to epithelial growth factor EGFR thus inhibiting the tyrosine kinase TYK pathways activation At present it is approved in over 35 countriesUS EU Canada and Japan not includedfor the treatment of serda adult Nimotuzumab TheraCIM hR3 is a humanized monoclonal antibody directed against human Epidermal Growth Factor Receptor EGFR EGFR signalling pathway is known to contribute to tumour proliferation apoptosis resistance angiogenesis invasion and metastasis TheraCIM is designed to target cells with particularly high expression of EGFR Head Neck Cancer Nimotuzumab TheraCIM hR3 Phase II study of nimotuzumab TheraCimhR3 concurrent with PubMed Theracim Basic Prescribing Info Contents Each 10 mL Nimotuzumab 50 mg dibasic Na phosphate 18 mg monobasic Na phosphate 45 mg NaCl 86 mg polysorbate 80 2 mg water for inj 10 mL MIMS Class Targeted Cancer Therapy ATC Classification L01FE EGFR Epidermal Growth Factor Receptor inhibitors Used in the treatment of cancer Mechanism of Action and Sources Nimotuzumab TheraCIM hR3 TheraCIM is designed to target cells with particularly high expression of EGFR therefore it can selectively bind to cancer cells with limited effect on healthy cells Once TheraCIM binds to EGFR on the cancer cell surface it deactivates the receptor and blocks the downstream signalling cascade EGFR targeting drugs have been shown to Theracim merupakan obat yang termasuk ke dalam golongan obat keras hanya dapat digunakan dengan resep dokter Penggunaan Theracim injeksi harus dibantu oleh tenaga ahli medis Diberikan secara infus intravena selama 30 menit Diphenhydramine sebelum terapi direkomendasikan untuk meminimalkan reaksi infus yang mungkin terjadi Drug Website Directory Medical Information MIMS Malaysia Nimotuzumab hR3 2 BIOMAb EGFR Biocon India 3 TheraCIM CIMYM Biosciences Canada Theraloc Oncoscience Europe CIMAher Center of Molecular Immunology Havana Cuba is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma and marketing approval in India China and other countries for squamous cell carcinomas of the head griyaslot and neck and was
amkop
xoix
